Ways to help
About us
Contact Us
Feb 2017
Trish Foundation contributes to first-ever discovery
Jun 2017
Researchers funded by the Trish Foundation making great progress
Dec 2017
Announcement by NHMRC
Jan 2018
2018 Round of Funding Four new Projects announced
Jun 2018
Exciting regrowth of nerve fibres
Jun 2018
Dr Merson secures $1 million from NHMRC
Jun 2018
Findings submitted for publication
Jan 2019
New Research Projects commencing 2019 announced

Work underway for two recent incubator

The Trish MS Research Foundation, in partnership with MS Research Australia, funded two short term incubator grants late in 2014. Incubator grants are awarded for new ideas in MS research to gather early pilot data which will then underpin further grant applications in the future.

Dr Ben Crossett from the University of Sydney received $22,000 to investigate neuromyelitis optica (NMO). Working with Associate Professor Michael Barnett, he is examining protein fragments which are displayed on the surface of cells in the body. These fragments form part of the immune response that goes awry in people with MS and NMO.

The majority of people with NMO have antibodies to a specific protein called aquaporin 4, but some do not. Of these people, it remains unclear whether they have a different subtype of NMO or a different disease and characterising the proteins in these people will help answer this question. Dr Crossett is establishing a sample collection of people with NMO and MS and optimising the techniques for this project which will employ brand new mass spectrometry equipment and novel data analysis to search for differences.

Dr Charles Galea from the Monash Institute of Pharmaceutical Sciences, received $25,000 for his project investigating the potential of cone snail venom to be used as a therapy for MS. The venom of cone snails contain a number of substances which are known to block potassium channels in immune cells.

Work undertaken previously by Dr Galea showed that drugs which block potassium channels reduced an MS-like illness in animal models. Dr Galea has performed an initial screen of the venom for protein fragments which are likely to bind to potassium channels and is now running experiments to test their binding ability. It is hoped that some of these compounds will be the basis of future research to develop new therapeutic drugs for MS.

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.